Prolynx is building a portfolio of extended-duration incretin and non-incretin medicines engineered for once-monthly or once-quarterly dosing to improve adherence and tolerability in obesity treatment. Its proprietary half-life extension platform, which has already shown clinical proof-of-concept in oncology, enables the creation of peptide drugs with markedly prolonged activity. The company is channeling its R&D toward IND-enabling studies and early clinical proof-of-concept for multiple obesity candidates. Newly appointed CEO Chris Boulton, a veteran of Amgen, Sanofi, and AstraZeneca, brings deep commercialization experience in metabolic disorders. Founders Daniel Santi and Gary Ashley continue to guide scientific strategy, with Santi serving as Chief Technical and Scientific Officer. Headquartered in Emeryville, California, Prolynx is backed by leading life-science investors and recently strengthened its balance sheet with a $70 million Series A to fund pipeline advancement.

Total raised

$70M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025